Luma AI Opens for International Business With Former WPP Executive Jason Day Leading New London Office
Luma AI, the frontier artificial intelligence company building multimodal AGI intelligence and known for its flagship product Dream Machine, today announced a major step in its global expansion with the opening of its first international office in London, UK.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251202217704/en/
LUMA AI OPENS FOR INTERNATIONAL BUSINESS WITH FORMER WPP EXECUTIVE JASON DAY LEADING NEW LONDON OFFICE
As creative economies decentralize and new production hubs emerge across EMEA, Luma AI is positioning its capabilities where creative work is increasingly being produced - not just consumed. To build intelligence that truly serves global creators, Luma AI will work alongside them in their markets, cultures, and workflows. London is the first step in that strategy, as it has the unique position as a global center of advertising, brands, and entertainment.
“With this Series C raise and the upcoming build-out of global compute infrastructure, we have the capital and capacity to bring world-scale AI to creatives everywhere,” said Amit Jain, CEO and co-founder of Luma AI. “Launching across EMEA is the logical next step in putting this power directly in the hands of storytellers, agencies, and brands globally.”
Luma AI expects to create 200 roles in London in 2026, across research, engineering, partnerships, and strategic development. By 2028, the company expects to significantly add roles across the UK, Europe, and Saudi Arabia as new workflows emerge in advertising, brands, and entertainment.
Jason Day Joins Luma AI as Head of EMEA
Jason Day, formerly Executive Vice President of Global Growth at Monks, will lead international business development, strategic partnerships, and customer expansion outside the United States. He brings more than 15 years of experience building global client relationships and scaling creative and technology teams across Europe, the Middle East, Africa, and Asia.
Before joining Monks, Day held senior roles at WPP - including Global Business Director and Director for WPP-Scangroup - and holds an MBA from the University of Oxford’s Said Business School. His background in operational excellence, P&L leadership, and talent development gives Luma AI a strong foundation for responsible growth in new markets.
“Jason brings a rare combination of commercial strategy, international growth experience, and deep understanding of the creative space,” said Caroline Ingeborn, COO of Luma AI. “His leadership across Monks and WPP - especially scaling large cross-border teams and building client relationships in markets like London. Munich and Riyadh make him the ideal leader to drive our next chapter. With Jason leading from London, Luma AI can bring creative intelligence directly into the hands of marketers and storytellers around the world.”
Day added: “Luma AI is the world leader in developing multimodal artificial generative intelligence (AGI) for the creative industry. Putting that intelligence into the hands of creative professionals around the world - be they marketers, gamers, or film studios - will transform the entire creative process. The regions we are expanding into are actively building new creative economies, with a need for technology that accelerates production without compromising quality. The potential for creative intelligence is still largely untapped, and this is the moment to scale it across industries and geographies.”
The expansion follows Luma AI’s recently announced $900 million Series C funding round. As part of the partnership, Luma AI will partner with HUMAIN on Project Halo - a 2-gigawatt supercluster designed to power large-scale AI systems to train and deploy large-scale multimodal World Models to build systems for AI-assisted production, simulation, education, design, and advertising.
About Luma AI
Luma AI is building a multimodal general intelligence that can generate, understand, and operate in the physical world. Its flagship platform, Dream Machine, enables creatives everywhere to generate professional-grade video and images. In 2025, Luma released Ray3, the world’s first reasoning video model capable of creating physically accurate videos, animations, and visuals. Luma’s models are utilized by top entertainment studios, ad agencies, and technology leaders, including Adobe and AWS, and are available via subscription or API. The company is backed by HUMAIN, Andreessen Horowitz, AWS, AMD Ventures, NVIDIA, Amplify Partners, Matrix Partners, and angels from across the technology and entertainment space. For more information, visit www.lumalabs.ai.
View source version on businesswire.com: https://www.businesswire.com/news/home/20251202217704/en/
Contacts
Peter Binazeski
Head of Communications
Luma AI
peter@lumalabs.ai
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com

Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
CorriXR Therapeutics, InhaTarget Therapeutics, and Merxin Ltd Announce Strategic Collaboration for the Development of Inhaled Lung Cancer Treatment2.12.2025 15:30:00 EET | Press release
CorriXR Therapeutics, an oncology-focused biotherapeutics company pioneering a ground-breaking gene editing platform technology, InhaTarget Therapeutics, a company dedicated to the early development and clinical validation of innovative treatments of pulmonary diseases by inhalation, and Merxin Ltd, a designer and supplier of inhaler devices, have entered a strategic collaboration to develop a pioneering inhaled genetic therapy targeting lung cancer. The partnership draws upon CorriXR’s proprietary CRISPR-based gene editing platform targeting NRF2, InhaTarget’s proprietary formulation platform and strong experience in pulmonary drug development, and Merxin Ltd’s advanced inhalation device technology. Through their combined expertise, they aim to create a patient-friendly inhaled therapy that delivers targeted treatment directly to lung tumors, maximizing efficacy, minimizing systemic side effects, and offering new hope for patients facing one of the world’s deadliest cancers. Innovativ
AdvanCell Initiates Phase 2 Expansion Trial of ADVC001, a Novel Targeted Alpha Therapy for Prostate Cancer2.12.2025 15:00:00 EET | Press release
AdvanCell, a clinical-stage radiopharmaceutical company developing innovative targeted alpha therapies for cancer, today announced the initiation of the TheraPb Phase 2 expansion trial (NCT05720130) evaluating its lead investigational candidate, ADVC001, in metastatic prostate cancer. The news follows the encouraging Phase 1b dose escalation results presented at the European Society for Medical Oncology (ESMO) 2025 congress that showed a favorable safety profile and compelling anti-tumor activity for ADVC001 in patients with mCRPC (see press release). ADVC001 is a first-in-class 212Pb-PSMA RLT in clinical development, with early data indicating a differentiated and competitive profile both within and beyond its class. Development is advancing rapidly; the Phase 1b therapeutic cohorts were enrolled within ten months, and the commencement of Phase 2 expansion sustains this strong program momentum. The TheraPb Phase 2 expansion will evaluate ADVC001 at two therapeutic dose levels – 160 MB
Aurigene Oncology Limited Announces Encouraging Initial Data From 1 st Two Cohorts of Phase 1 Study of AUR112, an Oral Small Molecule Inhibitor of MALT1, in Relapsed/Refractory Lymphoid Malignancies2.12.2025 15:00:00 EET | Press release
Aurigene Oncology Limited, a clinical-stage biopharmaceutical company developing novel therapies in oncology,today announced initial clinical results from 1st two cohorts of its ongoing Phase 1 clinical trial evaluating AUR112 in patients with relapsed or refractory lymphoid malignancies. Early findings show that AUR112 is safe, well tolerated, demonstrating meaningful clinical activity, with objective responses observed across multiple lymphoma subtypes, including Mantle Cell Lymphoma (MCL) and Marginal Zone Lymphoma (MZL). “We are very encouraged by the early results of the first two cohorts from our Phase 1 study of AUR112,” said Dr. Murali Ramachandra, CEO. “AUR112 has shown a promising initial clinical profile, achieving an overall response rate of 63.6% in the efficacy-evaluable population and 58.3% in the intent-to-treat group. These strong early data, combined with its distinct preclinical and safety characteristics, reinforce our belief that AUR112 has the potential to become
Eventbrite Enters into Definitive Agreement to Be Acquired by Bending Spoons for Roughly $500 Million to Accelerate Eventbrite’s Next Phase of Growth2.12.2025 14:30:00 EET | Press release
Eventbrite, Inc. (NYSE: EB), the leading global marketplace for shared experiences, announced today that it has entered into a definitive agreement to be acquired by Bending Spoons, in an all-cash transaction valued at approximately $500 million. The acquisition is subject to customary closing conditions and approvals, including regulatory approvals and approval by Eventbrite’s stockholders. “For two decades, Eventbrite has stood at the forefront of the experience economy, helping tens of millions to create, discover, and attend unforgettable events,” said Luca Ferrari, Bending Spoons CEO and Co-Founder. “Joining forces with Bending Spoons will accelerate innovation and strengthen Eventbrite’s tools and resources to bring even more people together through shared live experiences for many years to come. As longstanding fans, we’ve identified a few opportunities that we’re excited about exploring with the Eventbrite team after closing the transaction. These include building a dedicated m
Armis Recognized for Innovation; Named to Inc. Best in Business List for the Second Consecutive Year2.12.2025 14:00:00 EET | Press release
Armis, the cyber exposure management & security company, today announced that it has once again been named to Inc.’s Best in Business list, specifically highlighted in the Best in Innovation category for 2025. Inc.’s annual Best in Business Awards celebrate the exceptional achievements and contributions of companies that have made a profound impact on their industries and on society at large. “Armis rapidly innovates and continuously enhances our comprehensive Cyber Exposure Management Platform so that global organizations can proactively protect against cyber threats before there’s any impact,” said Yevgeny Dibrov, CEO and Co-Founder of Armis. “Unlike other solutions on the market, Armis addresses the entire lifecycle of managing cyber threats so that security teams no longer reactively respond to breaches. This is a strategic and monumental shift for the industry to stay a step ahead of threat actors and hugely beneficial to keeping society as we know it safe from disruptions.” Since
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom